A phase II experience evaluating quality of life and survival in linac-based SBRT for prostate cancer
Conclusion
SBRT with VMAT for low-intermediate risk prostate cancer is well tolerated. Acute toxicities showed no apparent impact on patient general sense of well-being. No adverse effects were observed over the 36 month period.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Health | Prostate Cancer | Study | Toxicology | Urology & Nephrology